Immatics Consolidated Income from 2010 to 2024
IMTX Stock | USD 11.10 0.27 2.37% |
Check Immatics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immatics main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 13.7 M or Interest Income of 14.5 M, as well as many exotic indicators such as Short Term Coverage Ratios of 43.83, Price To Sales Ratio of 13.5 or Dividend Yield of 0.0. Immatics financial statements analysis is a perfect complement when working with Immatics Valuation or Volatility modules.
Immatics | Consolidated Income |
About Immatics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Immatics income statement, its balance sheet, and the statement of cash flows. Immatics investors use historical funamental indicators, such as Immatics's Consolidated Income, to determine how well the company is positioned to perform in the future. Although Immatics investors may use each financial statement separately, they are all related. The changes in Immatics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immatics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Immatics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Immatics. Please read more on our technical analysis and fundamental analysis pages.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor based immunotherapies for the treatment of cancer in the United States. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers and Genmab AS to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 388 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immatics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immatics' short interest history, or implied volatility extrapolated from Immatics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Immatics Correlation against competitors. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Immatics Stock analysis
When running Immatics' price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Transaction History View history of all your transactions and understand their impact on performance | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |
Is Immatics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immatics. If investors know Immatics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immatics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.30) | Revenue Per Share 0.67 | Quarterly Revenue Growth (0.58) | Return On Assets (0.14) | Return On Equity (0.44) |
The market value of Immatics NV is measured differently than its book value, which is the value of Immatics that is recorded on the company's balance sheet. Investors also form their own opinion of Immatics' value that differs from its market value or its book value, called intrinsic value, which is Immatics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immatics' market value can be influenced by many factors that don't directly affect Immatics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immatics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immatics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immatics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.